Introduction
One of the major limitations of current gene therapy application is the low-level and transient proviral gene expression in target cells, as indicated by pilot retrovirusmediated gene therapy trials. [1] [2] [3] Therefore, the optimization of transgene expression cassette is a necessary approach toward the advancement of gene therapy protocol. Multiple factors may affect transgene expression, such as: (1) the promoter that regulates transgene expression in target cells; (2) the presence of a selectable marker which could introduce a survival advantage into transduced cells; and (3) potential 'promoter interference' or vector rearrangement which may cause the reduction or shut-off of the therapeutic gene following selection of the marker gene.
The use of strong, constitutive viral promoters does not usually result in long-term transgene expression in vivo; [4] [5] [6] [7] and promoter extinction occurs even in the presence of substantial amounts of vector DNA in transduced cells. 8, 9 This promoter inactivation is often observed in association with increased proviral methylation. activity per 1% relative transgene frequency in F MPS . Use of the same promoter to separately regulate both the therapeutic gene and a drug-resistance gene resulted in decreased expression of the unselected gene. Co-selection using bicistronic vectors not only increased the number of transductants, but also elevated transgene expression under selective pressure in transgene-positive progenitors. Bicistronic vector LP1CD overcame down-regulation and practically introduced the highest IDUA level in unselected PBL MPS and an intermediate level in PBPC MPS . These studies provide a better understanding of factors contributing to efficient gene expression in hematopoietic cells. Gene Therapy (2000) 7, 1875-1883.
addition, the cytokines interferon-␥ and tumor necrosis factor-␣ have been shown to inhibit transgene expression from several widely used viral promoters (CMV, RSV, SV40 and MMLV-LTR) delivered by retroviral, adenoviral, or plasmid vectors in vitro. 13 To enhance and stabilize the expression of transgenes in hematopoietic cells, some investigators have inserted into vector constructs promoters of certain housekeeping genes such as ␤-actin, 14, 15 thymidine kinase, 16 and phosphoglycerate kinase (PGK). 17, 18 However, data on parallel comparisons and evaluations of promoter strength have been insufficient due to differences in the reporter genes and retroviral vectors employed, and limited information on transduction frequency.
Dominant selectable markers, such as bacterial neomycin phosphotransferase (Neo R ) gene [19] [20] [21] and the dihydrofolate reductase (DHFR) gene, 22 have been utilized to introduce a survival advantage and corresponding selectivity into transduced hematopoietic cells. Although Neo R has been employed in hematopoietic cells in some studies, 23 this selection system cannot be applied in vivo due to the toxicity of neomycin. 24 Also, expression of such a bacterial gene in humans has the potential to act as a neo-antigen leading to an undesirable immunologic response. Antibodies against neomycin phosphotransferase have been found in the canine model of mucopolysaccharidosis I. 25 Introduction of an altered DHFR gene resulting in methotrexate (MTX) resistance would enable selection of the transduced cells in vivo, thus overcoming the temporal limitation for hematopoietic cell manipulation in vitro. 22 Use of MTX also has several advantages including (1) its long-standing use in non-malignant diseases; (2) the low incidence of cumulative toxicity associated with chronic use of MTX; 26 and (3) the absence of a discernible increase in risk for the development of secondary malignancies. 27 Furthermore, selection of a drug-resistant bone marrow containing a transgene may facilitate the development of long-term and stable transgene expression in vivo.
However, there is increasing evidence that the selection for a co-transduced marker gene may result in decreased expression of the unselected gene due to promoter interference during transcription. 19, 20, 28 Discovery of the internal ribosome entry site (IRES), identified in the long 5Ј-untranslated regions of picornaviruses, makes it possible to coexpress two genes from a bicistronic transcript through cap-independent translation initiation of the second gene. 29, 30 The application of this element for coexpressing a therapeutic gene and a drug-resistance gene has been reported in retrovirus-mediated gene transfer studies. [31] [32] [33] Mucopolysaccharidosis (MPS) type I is an autosomal recessive inborn error of glycosaminoglycan metabolism resulting from deficiency of ␣-L-iduronidase (IDUA). To optimize the retroviral vector design for hematopoietic stem cell gene therapy of MPS type I, we have constructed 10 retroviral vectors to evaluate the effects of selectable markers, promoter strength and suppression of transgene expression. The individual effect of vector design was investigated in primary fibroblasts from a patient with MPS I (F MPS ) or in murine fibroblast cell lines. An overall comparison of transgene expression was determined in patients' primary peripheral blood lymphocytes (PBL) and CD34
+ progenitor cells (PBPC). Hence, an optimized vector (LP1CD) may prove useful for stem cell gene therapy of MPS type I.
Results

Construction of IDUA retroviral vectors
To evaluate the potential effects of specific promoters, the addition of selectable markers, and promoter suppression on gene transfer and expression, 10 retroviral vectors were constructed to express human ␣-L-iduronidase cDNA ( Figure 1 ). The 10 vectors can be categorized into four types. The first type (L1SN) was a vector based on LXSN containing a bacterial Neo R gene regulated by the SV40 early promoter. The second group consisted of simplified vectors (L1, LB1 and LP1) lacking any selectable marker. The third vector group (L1BD, LB1BD and LP1BD) contained the IDUA gene along with a variant murine DHFR tyr22 cDNA driven by an internal ␤-actin promoter. The last group of vectors (L1CD, LB1CD and LP1CD) expressed an IDUA-DHFR bicistronic message by virtue of a cap-independent translational enhancer element (CITE sequence). For each vector, the IDUA cDNA was regulated by one of three different promoters: MMLV LTR, avian ␤-actin promoter or the human PGK promoter. All constructs were verified by restriction mapping and automated sequencing analysis. The PGK promoter demonstrated the highest efficiency of proviral IDUA expression in F MPS To assess the effect of different promoters on IDUA transgene expression, the same volume of simplified vectors (L1, LP1 and LB1) which differed only by the choice of promoters was utilized to transduce IDUA-deficient F MPS . Both IDUA specific enzyme activity and relative transgene frequency were evaluated in cells 22 days after transduction.
A fluorescence-based quantitative-competitive PCR assay was developed to measure the relative frequency of proviral IDUA sequence in F MPS (Figure 2 ). When cells were transduced with increasing amounts of LP1CD (multiplicity of infection from 0.2 to 8), the density of the genomic IDUA band was reduced as the signal from the proviral IDUA sequence intensified (Figure 2a) . Greater sensitivity and more reliable quantification were obtained from fluorescence detection in comparison with densitometry after electrophoresis (Figure 2b) . Moreover, the relative transgene frequency (density of proviral IDUA: genomic IDUA) in F MPS derived from this quantitation was strictly proportional to the MOI (virus:cells) (Figure 2c ), implying the accuracy of the fluorescentbased quantitative-competitive PCR technique.
The relative transgene frequency was higher in cells transduced with LB1 (39.0 ± 12.7%) than those with LP1 (6.4 ± 1.9%) or L1 (3.1 ± 0.8%) ( Table 1) . However, cells transduced with LP1 vector exhibited the highest IDUA enzyme activity (403 ± 6 U/mg/h) as compared with those transduced with LB1 (162 ± 29 U/mg/h) and L1 (93 ± 25 U/mg/h). Therefore, vector LP1 introduced the highest average IDUA activity (63.0 U/mg/h/% transgene frequency) into F MPS transductants in comparison to The MOI was determined by transducing F MPS with LP1CD at known MOI using quantitative-competitive PCR method ( Figure 2 ). The IDUA activity in the non-transduced F MPS cells was undetectable. d Individual clones isolated from transduced populations by plating at low density were assayed for proviral IDUA sequence by PCR. Transgene-positive clones (+clones) (9-14 for each vector) were then analyzed for IDUA enzyme activity.
vector L1 (30.0) and vector LB1 (4.2). In addition, a higher range of IDUA activities was observed in clones positive for LP1 (ranging from 21 U/mg/h to 900 U/mg/h) than for L1 (58 to 115) or LB1 (29 to 73) proviruses. These results indicated that the PGK promoter was stronger than MMLV-LTR and ␤-actin promoter in human primary fibroblasts.
A remarkable difference in upstream IDUA expression observed in MTX-resistant clones derived from PA317 cells To evaluate the effect of multiple internal promoters on IDUA expression, PA317 clones derived from each of the six vectors containing DHFR tyr22 were selected with MTX and assayed for IDUA enzyme expression (Table 2) . When DHFR was regulated by a separate ␤-actin promoter downstream of IDUA, fewer than half of the MTXresistant clones expressed high levels (Ͼ20-fold above background level) of IDUA activity. Clones of L1BD vector appeared to have relatively less down-regulation of Gene Therapy IDUA expression (48% of clones with high IDUA activity) compared with vectors containing an internal promoter (21% of LP1BD clones and 10% of LB1BD clones). In contrast, more than 94% of drug-resistant clones containing bicistronic vectors (L1CD, LP1CD and LB1CD) exhibited significantly high levels of IDUA transgene, indicating the overcome of the down-expression of transgene observed. Notably, IDUA activity was the same as background level in significant number of MTX-resistant PA317-L1BD (three of 31), PA317-LP1BD (four of 19) and LB1BD (13 of 39) clones, but none in those derived from bicistronic vectors. Surprisingly, IDUA activity was even undetectable in a considerable number of drug-resistant PA317-LP1BD (four out of 19) and PA317-LB1BD (11 out of 39) clones, but in none of those derived from the other vectors. Interestingly, when both IDUA and DHFR were expressed from independent ␤-actin promoters on the same vector (ie cells transduced with LB1BD), a maximum IDUA level of 3130 nmol/mg/h was observed in derivative clones, a level which was only 1/10 of that (Table 3 ). Transduced cells were cultured for an additional 16 days, collecting cell samples every 5-6 days. In all transduced PBL MPS cells, specific IDUA activities were at the highest point (up to 5000 nmol/ml/h) 1 day after transduction and decreased dramatically to a low steady-state level on day 7, suggesting a biphasic phenomenon (data not shown). This pattern is consistent with our previous studies on iduronate-2-sulfatase (IDS), 34 which demonstrated the uptake of recombinant IDS enzyme released by the packaging cells, with subsequent consumption of enzyme during the first phase. The half-life of this component was approximately 2-3 days (data not shown). After 16 days in culture, the observed levels of IDUA activity, attributable at this point in time to proviral IDUA expression, were higher than background in all transduced PBL MPS (Table 3) . Except for vector LB1BD, normal or higher-than-normal levels of IDUA activity were found in all nonselected PBL MPS populations transduced with any of the other nine vectors. Among them, the highest level (1134 nmol/mg/h) was observed in PBL MPS -LP1CD, which was approximately 10 fold higher than the level in normal PBL (65-150 nmol/mg/h).
To select the most practical vector for gene transfer into hematopoietic stem cells, each of the 10 retroviral constructs was evaluated for overall IDUA transgene expression in PBPC MPS using 10 ml of each vector supernatant (20 ml of L1BD-and L1CD-containing supernatant were used due to the low titers in their producing cell lines). After 3 days preculture, IDUA-deficient CD34 Interestingly, PBPC MPS transduced with vectors containing an internal human PGK promoter (LP1, LP1BD and LP1CD) always exhibited the highest IDUA activities (three-to nine-fold) in comparison with other vectors sharing similar design but carrying different promoters, althrough MOI varied among vectors. These IDUA levels were also within or higher than the normal range (91 ± 17 nmol/mg/h).
IDUA expression was increased under the pressure of MTX selection in short-term progenitor cultures of transduced PBPC MPS Co-transcription of both IDUA and DHFR cDNA in the same bicistronic message might provide co-selection of higher IDUA activity under MTX selective pressure. To test this hypothesis, CD34
+ cells transduced with LP1CD were cultured for 10-12 days in methylcellulose medium
Figure 3 Comparison of IDUA transgene expression in transduced PBPC MPS . Progenitor cells were transduced twice per day (3-h vector exposure) on 2 consecutive days. Solid bars represent the IDUA levels in cells 10 days after the last vector exposure. Shaded area indicates the normal range of IDUA level in PBPC (91 ± 17 nmol/mg/h).
in the presence of 0, 35 and 50 nm MTX (Figure 4 ). Without MTX selection, progenitor-derived colonies contained 23 ± 12 nmol/mg/h IDUA activity in the bioreactortransduction experiments and 13 ± 9 nmol/mg/h in the bag-transduction experiments. After selection in 35 nm MTX (resulting in the absence of any surviving colonies in the nontransduced control cultures), the drug-resistant cells exhibited up to 143 nmol/mg/h IDUA activity in bioreactor-transduction experiments and 127 nmol/mg/h in bag-transduction experiments. Interestingly, under greater selective pressure (50 nm MTX), an even higher level of IDUA expression (361 nmol/mg/h or 337 nmol/mg/h) was observed in the drug-resistant cells derived from PBPC MPS -LP1CD in both procedures. These results demonstrated the capacity of bicistronic vectors for co-selection of transduced cells expressing higher levels of IDUA activity.
Discussion
Transcriptional regulatory elements are important vector components for optimization of sustained transgene expression. However, the effects of different promoters on gene expression still remain unclear, due to the variety of retroviral vector systems tested and the limited information on side-by-side comparison of promoters and transduction frequency. 35 The MMLV-LTR is a widely used strong viral promoter. However, high transcriptional inactivity of the LTR has been observed in the progeny of hematopoietic stem cells in murine bone marrow Gene Therapy
Figure 4 Effect of MTX selection on IDUA transgene expression in PBPC MPS transduced with LP1CD. One day after the last vector exposure period, transduced PBPC MPS cells were cultured in defined methylcellulose medium for 10-12 days in the presence of 0, 35 and 50 nm MTX. No colony formation was observed in nontransduced control cultures under selection with 35 nm MTX. Each data point represents an average of two to three experiments. Each experiment was performed in duplicate.
transplant recipients 8, 9 which may be related to methylation of proviral LTR 10, 12 and cytokine-regulated inhibition of viral promoters. 13 However, modifications of LTR, such as replacing the U3 enhancer of the 3Ј LTR with the erythroid-specific GATA-1 autoregulatory enhancer, have demonstrated enhanced and targeted transgene expression in erythroblastic progeny of transduced stem cells. 36 To stabilize transgene expression in hematopoietic cells, some investigators have tested internal promoters in retroviral vector constructs. The avian ␤-actin promoter has shown the capacity for highlevel expression in murine hematopoietic cell transplantation studies. 14, 15 However, in vitro studies of transduced human leukemia cell lines have found the human ␤-actin promoter to be a relatively weak promoter. 16 The human PGK promoter, on the other hand, has been associated with strong transgene expression in hematopoietic cells 17, 18 and long-term therapeutic effects in cells reconstituted with transduced bone marrow in mice. 37 We evaluated the activity of the MMLV-LTR, ␤-actin and PGK promoters in simplified retroviral constructs to obviate the potential impact of selection on transgene expression. The human PGK promoter conferred the highest level of IDUA activity per 1% relative transgene frequency in human primary fibroblasts. Moreover, when PBPC MPS were transduced with the same volume of supernatant containing each of the 10 retroviral vectors in this study, those containing an internal human PGK promoter (LP1, LP1BD and LP1CD) exhibited the highest IDUA activities (three-to nine-fold) compared with other vectors sharing similar design but carrying different promoters (excluding L1SN which had one-log-fold greater titer). Notably, these higher levels were not correlated with relative MOI. All PGK-containing vectors enabled the transduced PBPC MPS to express IDUA activity within or above the normal range in progenitor cells. These results suggested that the PGK promoter is an effective promoter and may be one of the best candidates for transgene expression in hematopoietic progenitor cells.
The effect of selection for the DHFR transgene on expression of IDUA was evaluated in PA317-based packaging clones using vectors expressing the two genes as one bicistronic or two monocistronic transcripts. When driven by separate promoters (L1BD, LP1BD and LB1BD), active expression of DHFR (due to selection pressure) was associated with a high level of IDUA activity in less than 50% of the clones. However, when the two genes were co-expressed in a bicistronic message (L1CD, LP1CD and LB1CD), more than 94% of the drugresistant clones exhibited high-level IDUA activity (Table 2) . Thus, such bicistronic vectors may have the potential to provide increased expression of IDUA as part of an in vivo selection strategy. Moreover, 13 out of 39 PA317-LB1BD clones demonstrated only the background level of IDUA, a rate which was much higher than clones derived from any other vectors. This result is consistent with previous observations that directly repeated sequences are deleted at very high frequencies in murine leukemia virus-based vectors. 38 This phenomenon may be related to template misalignment during reverse transcriptase template switching in the process of replication of viral RNA into double-stranded DNA. 39 Interestingly, the maximum IDUA activity in PA317-LB1BD clones was only about 1/10 of that in cells containing other vectors. Thus, the use of the same promoter to regulate both a therapeutic gene and a drug-resistance gene separately was the least effective vector design tested in this series.
A major impediment to the practical application of hematopoietic stem cell gene therapy is the extremely low efficiency of transduction using currently available gene delivery systems. 3, 40 In vivo selection may be a useful strategy for increasing the proportion of transduced stem cells and their progeny by conferring resistance to a subsequently administered cytotoxic drug. 41 Previous studies on DHFR gene transfer and MTX administration in murine models have demonstrated increasing survival and a significantly higher hematocrit during MTX treatment compared with controls. 22, 42 Although some complexities in the use of MTX for in vivo selection are exemplified in studies using murine models, 43 a systemic chemoprotective effect has been observed in mice transplanted with transgenic marrow expressing MTX-resistant DHFR. 44 Moreover, studies on in vivo selection of retrovirally transduced bone marrow cells have shown increased percentage of vector-expressing peripheral blood erythrocytes, platelets, granulocytes, and T and B lymphocytes. 45 This selection occurred at the level of hematopoietic stem cells as demonstrated by secondary transplantation experiments.
In the current study, the vector LP1CD provided not only a dominant DHFR marker for in vitro and potential in vivo selection, but also a positive influence on the expression of therapeutic IDUA cDNA. The strategy of simultaneously expressing both the therapeutic gene and the drug-resistance gene from a single transcript eliminates any possibility for promoter suppression arising in vectors containing multiple promoters. Moreover, the results in progeny derived from PBPC MPS -LP1CD demonstrate that the IDUA enzyme activity increased with greater stringency of MTX selection. It is speculated that this property of co-expression may thus provide positive pressure for increasing expression of non-selectable IDUA in transduced cells. This characteristic would be particularly beneficial in stem cell gene therapy for which silencing of transgenes has been identified as a significant challenge in previous studies. 8, 11, 46 Pilot retrovirus-mediated gene therapy trials have indicated that each individual application of gene therapy ultimately depends upon an interplay of the promoter(s) utilized, the vector type and potency, the specific types of cells targeted, and the transduction protocol employed. 40, 47 For instance, the activities of retroviral vector-encoded promoters may vary in an unpredictable manner from cell type to cell type. 16 Therefore, we comparatively evaluated the 10 retroviral vectors for overall IDUA expression in both enzyme-deficient PBL MPS and PBPC MPS (Table 3, Figure 3) . In a comparison of the response to equal volumes of vector supernatants, PBL MPS transduced with LP1CD achieved the highest IDUA activity. This level was approximately 10-fold greater than that observed in normal PBL, thus suggesting tremendous over-expression of the IDUA cDNA from LP1CD provirus. In addition, vector LP1CD was capable of expressing normalized IDUA level in PBPC MPS (at an MOI of 1).
In conclusion, vector LP1CD had the following advantages of: (1) bearing a PGK promoter which exhibited strong activity in human primary fibroblasts, peripheral blood lymphocytes and CD34 + progenitor cells; (2) coexpression of the target gene and the selectable marker gene in a bicistronic message so to elude the downexpression of the unselected gene observed in cells transduced with vectors containing multiple promoters; and (3) introduction of a co-selection capacity with the potential to initiate a increased and sustained IDUA expression by in vivo selection. Practically, vector LP1CD expressed the highest IDUA activity in PBL MPS and an intermediate level into PBPC MPS without selection. Together, these observations suggested that LP1CD, among the 10 vectors tested in this study, may be the most suitable vector for a clinical trial of PBPC gene therapy for MPS I.
Materials and methods
Isolation of human IDUA cDNA and construction of LISN The human IDUA cDNA was generated by RT-PCR amplification (sense primer 5Ј-agc ccg aat tcc cgc agt cc-3Ј; antisense primer 5Ј-aag ctt ggt gga ggt gga tcc cac tgg g-3Ј) from the total cytoplasmic RNA isolated from normal PBL using TRIzol Reagent (GibcoBRL, Grand Island, NY, USA). The RT-PCR product was subcloned into an expression plasmid pLXSN 48 between EcoRI and BamHI sites. The primary positive clones (13 out of 43), which had inserts with the predicted size and the correct restriction mapping, were transfected individually into an ecotropic packaging cell line GP+E86. 49 After G418 (Geneticin; Sigma, St Louis, MO, USA) selection (0.4 mg/ml) for 3 days, two out of 13 candidate clones introduced high (up to 5.5-fold above background) levels of IDUA activity into derived culture medium, indicating the appropriate catalytic function and intracellular traf-ficking of the cloned IDUA cDNA sequence. Clone pL1SN-33 was selected for confirmatory sequencing and further studies.
Generation of CITE-DHFR fragment and construction of nine other retroviral vectors
The CITE sequence (2337-2917 from plasmid pCITE-1, Novagen, WI, USA) was amplified using an antisense primer (5Ј-ggt cga acc ata taa tca tcg tg-3Ј) containing an 8-bp adapter complementary to DHFR cDNA (from the start codon) at the first AUG site (bases 2915-2917) of the CITE fusion site. A murine DHFR tyr22 cDNA sequence 50 was employed carrying a mutation coding for a leucine to tyrosine substitution at codon 22. The specially designed sense primer for DHFR (5Ј-gat tat atg gtt cga cca ttg aac tgc atc gtc gcc g-3Ј) contained a 6-bp 5Ј-adapter which was the same sequence occurring upstream of the 2915-2917 AUG of the CITE sequence. With a 17-bp overlap, the CITE sequence was joined with DHFR in the proper reading frame by recombinant PCR using primers to incorporate BamHI sites at both ends of the CITE-DHFR fragment. The CITE-DHFR BamHI fragment was subcloned into the plasmid pL1 from which primary clones were analyzed by restriction mapping and PCR amplification. 
DNA sequencing
All sequencing analysis was conducted using the Dye Terminator Cycle Sequencing Ready Reaction Kit (ABI PRISM) with AmpliTaq DNA Polymerase (Perkin Elmer, Foster City, CA, USA) on a thermal cycler (Perkin Elmer, 9600 model). Reaction conditions were 10 s at 96°C, 5 s at 50°C and 4 min at 60°C for 25 cycles after incubating at 96°C for 1 min. Fluorescent signals from the sequencing gels were analyzed by an automated sequencer (Applied Biosystems; 373A). The experimental data were then assembled and aligned using the Sequencher 3.0 software (Gene Codes, Ann Arbor, MI, USA) with sequences from GenBank database.
Shuttle packaging and titration assay
To establish high-titer vector-producing cell lines, all constructs were shuttle-packaged through an ecotropic packaging cell line GP+E86 into an amphotropic packaging cell line PA317. 51 Vectors without any selectable marker were co-transfect with pSV-D tyr22 , 50 at a ratio of 1:2 (construct:pSV-D tyr22 ) into GP+E86 cells followed by MTX selection for 14 days. Viral supernatants from stable transfectants were used to transduce PA317 cells at 3 ml/5 × 10 5 cells, followed by subculturing cells at low density to obtain clones. Individual packaging clones for all 10 constructs (18-45 for each construct) were collected after more than 30 days of either selection (with 0.4 mg/ml G418 or 250 nm MTX) or expansions, and screened for both IDUA expression and viral titer (see below). Selectable vectors were titered in NIH 3T3 cells using suitable dilutions of viral aliquots in the presence of 8 g/ml polybrene (Sigma) for 24 h, subculturing 1:10 into selective medium containing 100 nm MTX or 0.4 mg/ml G418. All samples were tested in duplicate. The titers of LI, LP1 and LB1 were determined by quantifying the amount of integrated proviral sequences after fluorescent quantitative-competitive PCR assay (see below for details) from infected F MPS . The assay was calibrated by infecting cells with dilutions of LP1CD supernatant of known titer.
Fluorescent quantitative-competitive PCR assay A frozen pellet was resuspended at 2 × 10 6 cells/ml in a solution of nonionic detergents NP 40 (0.45%) and Tween 20 (0.45%) with proteinase K (60 g/ml). 52 Cells were lysed at 56°C for 1 h and then incubated at 95°C for 20 min to inactivate proteinase K. The sense primer (5Ј-tcc agg aca gca acc aca cg-3Ј) labeled with fluorescent FAM dye (Applied Biosystems) and the unlabeled antisense primer (5Ј-ccg gaa ctg ctc tgc cgt gg-3Ј) were specific to exon 9 and exon 10. Reaction conditions for 35 cycles were: denaturation for 45 s at 95°C, annealing for 45 s at 61°C, and extension for 30 s at 72°C. Owing to competition between proviral and genomic IDUA sequences, the change in the ratio of brightness of the genomic (366 bp) and proviral (275 bp) bands corresponded to the ratio of templates between provirus and genome. PCR products were separated by electrophoresis on a 4% denaturing acrylamide gel and analyzed using the automated DNA analyzer by Genescan software (Applied Biosystems) for accurate sizing and quantitation of the fluorescent bands.
IDUA fluorometric enzyme assay Fluorogenic substrate 4-methylumbelliferyl ␣-L-iduronide 4MU-IDUA (Calbiochem No. 474525, CA, USA) was utilized to assess IDUA enzyme activity at 37°C as previously described. 53 Protein concentration was measured with Coomassie blue (BioRad, Hercules, CA, USA) by the Bradford method. 54 IDUA specific activity of each sample was calculated as nmol/mg protein/h. All samples were assayed in duplicate.
Maintenance and transduction of human cells
The F MPS (GM00415, Human Genetic Mutant Cell Repository, Camden, NJ, USA) were maintained in Dulbecco's Modified Eagle Medium (DMEM) (GibcoBRL) containing 20% newborn calf serum (NCS) (Hyclone A-2170-D), 2 mm glutamine (GibcoBRL 25030-081), 50 units/ml penicillin, 50 mg/ml streptomycin and 125 ng/ml amphotericin B (GibcoBRL). Cells were plated at 3 × 10 5 per flask 15 h before retroviral vector exposure, and transduction was carried out in the presence of 8 g/ml polybrene.
Fresh PBL (leukapheresis product) were isolated by equilibrium centrifugation with Ficoll 1.077 (Histopaque-1077, Sigma H8886) at 500 g for 30 min. The cells were then stimulated by 10 ng/ml anti-CD3 monoclonal anti-
